Abstract Submission

Regular and Late-Breaking Abstract submission has now closed! Notifications will be sent to presenting authors by the end of the day on December 5, 2025. Stay tuned for presentation guidelines coming soon!

Important Dates

Friday, August 1 - Friday, October 17 Regular Abstract Submission (No Extension)
Monday, October 20 - Friday, November 7 Late-Breaking Abstract Submission
December 5, 2025 Notification of Abstracts

Late-Breaking Abstract Submission

Monday, October 20, 2025 – Friday, November 7, 2025

Notifications will be sent to presenting authors by the end of the day on December 5, 2025.

ACTRIMS is seeking up to 4 abstracts for oral platform presentation during the Late-Breaking Research and Clinical Trials session on Saturday, February 7. This session is not CE-accredited, and ACTRIMS welcomes submissions from commercial interests/industry.

High-impact clinical trials will be prioritized in the review of abstracts for this session, but the session may also include highly impactful results that could not have been ready for submission by the regular deadline. For the latter, a statement of why the abstract could not have been submitted by the regular deadline will be required. Selection for platform presentation is expected to be highly competitive. If space allows, abstracts that meet the high barrier for inclusion in this session but are not selected for platform presentation may be accepted for poster presentation in a dedicated section of the poster sessions.

Regular Abstract Submission

Friday, August 1, 2025 - Friday, October 17, 2025 - CLOSED

Notifications will be sent to presenting authors by the end of the day on December 10, 2025.

ACTRIMS encourages the submission of abstracts on any research or clinical topic related to MS and other neuroimmunological disorders. Abstracts should contain original scientific material, including results of research studies, case series, descriptions of cases of extraordinary interest, and protocol design, which must not be published or have been presented at the time of submission. Abstracts containing review of existing literature, other than systematic reviews and meta-analyses that follow PRISMA guidelines, as well as opinion/editorials, will not be accepted.

Abstracts are NOT restricted to studies that fall under the theme of this year’s Forum. Similarly, abstracts selected for oral platform presentations in the “Emerging Concepts in MS” or “Cutting Edge Developments” sessions will not be restricted by the theme of the Forum.

Abstract Preparation

  1. Abstracts must be submitted online via the abstract submission site. Abstracts submitted by email or fax will not be accepted.

  2. Titles must be submitted in title case, e.g. “Safety of New MS Therapies.”

  3. The abstract text contains 4 mandatory sections: background & objectives, methods, results, and conclusions. The full abstract text may not exceed 2,500 characters, excluding spaces.

  4. A primary keyword must be selected during the abstract submission process (see list below).

  5. Abstracts should contain original material not published or presented at the time of submission.

  6. Abstracts must be submitted in English. Please use American English spelling.

  7. All abbreviations must be defined the first time they appear in the text, e.g. Multiple Sclerosis Impact Scale (MSIS). Do not define abbreviations in the title.

  8. Use the abstract submission site functions for Greek letters, mathematical symbols, special characters, and formatting. Avoid complex mathematical formulae.

  9. Use generic drug names.

  10. Tables, charts, or other graphics may not be included.

  11. The presenting author of an accepted abstract must register and attend the ACTRIMS Forum.

    • Biomarkers and Metabolomics

    • Clinical Measures and Assessment

    • Clinical Trials

    • Diagnosis and Differential Diagnosis

    • Digital Tools

    • Disease Mechanisms and Pathogenesis

    • Imaging

    • Non-MS Neuroimmune Conditions

    • Patient Demographics and Epidemiology

    • Real-World Evidence

    • Regeneration and Protection

    • Symptom Management and Comorbidities

    • Therapeutics Development

  • This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Interstate Postgraduate Medical Association (IPMA) and ACTRIMS. IPMA is accredited by ACCME to provide continuing education (CE) for physicians.

    The rules governing eligibility of scientific meetings for CE are complicated and continually evolving, in particular, the rules related to submissions involving commercial interests (as defined by ACCME). Please note the following policies concerning abstracts for this meeting, some of which may differ from those of other scientific meetings you may have attended.

    Abstracts accepted for oral platform presentation, for which CE credits will be offered, will be designated as such and will be clearly distinguished from non-CE work. For your submission to be included in a session that meets the requirements for AMA Category I credit and adheres to ACCME guidelines, it must meet each of the following criteria:

    1. In general, no author may be an employee of a commercial interest. Exceptions will require prior approval by our joint sponsors.

    2. The abstract, presentation, or slides may not be written, prepared, or produced by a commercial interest.

    3. The submission must be non-promotional in nature.

    4. The content must be appropriate in depth and scope for the intended physician audience.

    5. All presenting authors must complete and sign the disclosure form.

    CE will not be offered for poster presentations or the Late-Breaking Research and Clinical Trials session.

  • Abstracts with authors who are employees of commercial interests, including abstracts solely from commercial interests, will be considered for non-CE sessions or poster presentations.

    Abstracts reporting results from collaborative research conducted by both independent investigators (including academic, investigators) and investigators who are employees of commercial interests will not be accepted unless the independent investigators are included as authors.

  • ACTRIMS follows a modified position of the Committee on Publication Ethics regarding authorship and AI tools. Authors who use AI tools in the writing of an abstract, production of images or graphical elements of a presentation, or collection and analysis of data, must be transparent in disclosing in the Materials and Methods (or similar section) of the abstract and presentation how the AI tool was used and which tool was used. Authors are fully responsible for the content of their manuscript, even those parts produced by an AI tool, and are thus liable for any breach of publication ethics.

  • There is no limit to the number of abstracts that an author can submit.

  • Each abstract will be sent for review to at least three external experts. Each reviewer will receive author name(s) and affiliation(s) along with the abstract and will be asked to declare conflicts of interest with individual abstracts. Upon completion of the external review, the final decision of acceptance or rejection will be made by the ACTRIMS Program Co-Chairs in consultation with the Scientific Program Committee.

    Notification of acceptance or rejection of submitted abstracts will be sent to presenting authors via email in early December 2025.

    • The presenting author of an accepted abstract, poster or platform, must register and attend the ACTRIMS Forum.

    • Abstracts chosen for oral platform presentation in Session 1, Cutting Edge sessions, or the Late Breaking and Clinical Trials session will NOT be presented in poster form.

    • If your abstract has been accepted as poster presentation, you will be asked to prepare a poster in paper and electronic format (ePoster).

  • Abstract titles will be released on Friday, January 16, 2026.

    All accepted abstracts will be published in the ACTRIMS Forum 2026 Abstract Catalog and the Multiple Sclerosis Journal online.

    • Full text of Regular Abstracts is embargoed until published on Monday, January 26, 2026.

    • Full text of Cutting Edge Session Abstracts is embargoed until published on Thursday, February 05, 2026.

    • Full text of Late-Breaking Abstracts is embargoed until published on Saturday, February 7, 2026.

  • The presenting author of an accepted abstract must register and attend the ACTRIMS Forum 2026. The presenter registration deadline is Wednesday, January 14, 2026. Presenters who do not register by this deadline will be dropped from the program. Please note that all presenters are responsible for their own registration expenses.

  • An accepted abstract should be withdrawn only under extraordinary circumstances. If you are unable to find a replacement presenter and must withdraw your presentation, please notify Keri Lore at klore@actrims.org by Wednesday, January 28, 2026.

  • Sharing news and information about ACTRIMS Forum 2026 through social media is encouraged within the embargo restrictions. Please use the official hashtag in all posts: #ACTRIMSForum